Want to see PL:RVU full AI Analyst Report?

Ryvu Therapeutics SA (RVU) Price & Analysis

0 Followers

RVU Stock Chart & Stats

zł27.65

Market closed

zł27.65

Day’s Range― - ―

52-Week Rangezł13.64 - zł32.50

Previous CloseN/A

VolumeN/A

Average Volume (3M)26.70K

Market Cap

zł350.50M

Enterprise Valuezł367.86M

Total Cash (Recent Filing)zł79.05M

Total Debt (Recent Filing)zł73.64M

Price to Earnings (P/E)―

Beta1.02

Next Earnings

Sep 10, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-3.86

Shares Outstanding23,120,148

10 Day Avg. Volume24,770

30 Day Avg. Volume26,695

Financial Highlights & Ratios

PEG Ratio0.68

Price to Book (P/B)11.64

Price to Sales (P/S)10.06

P/FCF Ratio-5.32

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)0.57

Revenue Forecast (FY)zł133.73M

Bulls Say, Bears Say

Bulls Say

Revenue GrowthThe company's strong revenue growth rate indicates expanding operations and potential market capture, which is crucial for long-term sustainability in the competitive biotech industry.

Gross Profit MarginA strong gross profit margin suggests effective cost management and pricing power, which can support future profitability as the company scales its operations.

Cash Flow GrowthPositive free cash flow growth indicates improving cash generation ability, which is essential for funding R&D and supporting strategic initiatives without relying heavily on external financing.

Bears Say

Profitability ChallengesOngoing profitability issues highlight difficulties in converting revenue into net income, which could hinder long-term financial health and investment in growth opportunities.

Operating Cash FlowNegative operating cash flow suggests the company is not generating sufficient cash from its core operations, potentially limiting its ability to sustain growth and meet financial obligations.

Return On EquityNegative return on equity reflects inefficiencies in using shareholder funds to generate profits, which could deter investors and affect the company's ability to raise capital.

RVU FAQ

What was Ryvu Therapeutics SA’s price range in the past 12 months?

Ryvu Therapeutics SA lowest stock price was zł13.64 and its highest was zł32.50 in the past 12 months.

What is Ryvu Therapeutics SA’s market cap?

Ryvu Therapeutics SA’s market cap is zł350.50M.

When is Ryvu Therapeutics SA’s upcoming earnings report date?

Ryvu Therapeutics SA’s upcoming earnings report date is Sep 10, 2026 which is in 66 days.

How were Ryvu Therapeutics SA’s earnings last quarter?

Ryvu Therapeutics SA released its earnings results on May 20, 2026. The company reported -zł0.547 earnings per share for the quarter, missing the consensus estimate of N/A by -zł0.547.

Is Ryvu Therapeutics SA overvalued?

According to Wall Street analysts Ryvu Therapeutics SA’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Ryvu Therapeutics SA pay dividends?

Ryvu Therapeutics SA does not currently pay dividends.

What is Ryvu Therapeutics SA’s EPS estimate?

Ryvu Therapeutics SA’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Ryvu Therapeutics SA have?

Ryvu Therapeutics SA has 23,120,148 shares outstanding.

What happened to Ryvu Therapeutics SA’s price movement after its last earnings report?

Ryvu Therapeutics SA reported an EPS of -zł0.547 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.658%.

Which hedge fund is a major shareholder of Ryvu Therapeutics SA?

Currently, no hedge funds are holding shares in PL:RVU

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Ryvu Therapeutics SA

Ryvu Therapeutics S.A. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing novel small molecule treatments for oncology. Their primary experimental drug, RVU120, functions as a CDK8 kinase inhibitor and shows promise for development across hematological malignancies and solid tumors. This compound is presently in a Phase 1b clinical study for the treatment of acute myeloid leukemia and myelodysplastic syndrome. Among their other assets is SEL24/MEN1703, a dual PIM/FLT3 kinase inhibitor licensed to the Menarini Group, which is currently undergoing a Phase 2 clinical trial for acute myeloid leukemia. Furthermore, Ryvu's earlier research pipeline explores candidates in areas such as kinases, cancer metabolism, synthetic lethality, and immuno-oncology. The company, established in 2007, is based in Kraków, Poland.